Circulating miRNA biomarkers for Alzheimer's disease.

A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is required to select optimal patient groups in clinical trials, monitor disease progression and response to treatment, and to better plan patient clinical care. Blood is an attractive source for biomarkers du...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pavan Kumar, Zoltan Dezso, Crystal MacKenzie, Judy Oestreicher, Sergei Agoulnik, Michael Byrne, Francois Bernier, Mamoru Yanagimachi, Ken Aoshima, Yoshiya Oda
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d506b339c5284f2390f8cbdf863dd996
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d506b339c5284f2390f8cbdf863dd996
record_format	dspace
spelling	oai:doaj.org-article:d506b339c5284f2390f8cbdf863dd9962021-11-18T09:02:24ZCirculating miRNA biomarkers for Alzheimer's disease.1932-620310.1371/journal.pone.0069807https://doaj.org/article/d506b339c5284f2390f8cbdf863dd9962013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23922807/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is required to select optimal patient groups in clinical trials, monitor disease progression and response to treatment, and to better plan patient clinical care. Blood is an attractive source for biomarkers due to minimal discomfort to the patient, encouraging greater compliance in clinical trials and frequent testing. MiRNAs belong to the class of non-coding regulatory RNA molecules of ∼22 nt length and are now recognized to regulate ∼60% of all known genes through post-transcriptional gene silencing (RNAi). They have potential as useful biomarkers for clinical use because of their stability and ease of detection in many tissues, especially blood. Circulating profiles of miRNAs have been shown to discriminate different tumor types, indicate staging and progression of the disease and to be useful as prognostic markers. Recently their role in neurodegenerative diseases, both as diagnostic biomarkers as well as explaining basic disease etiology has come into focus. Here we report the discovery and validation of a unique circulating 7-miRNA signature (hsa-let-7d-5p, hsa-let-7g-5p, hsa-miR-15b-5p, hsa-miR-142-3p, hsa-miR-191-5p, hsa-miR-301a-3p and hsa-miR-545-3p) in plasma, which could distinguish AD patients from normal controls (NC) with >95% accuracy (AUC of 0.953). There was a >2 fold difference for all signature miRNAs between the AD and NC samples, with p-values<0.05. Pathway analysis, taking into account enriched target mRNAs for these signature miRNAs was also carried out, suggesting that the disturbance of multiple enzymatic pathways including lipid metabolism could play a role in AD etiology.Pavan KumarZoltan DezsoCrystal MacKenzieJudy OestreicherSergei AgoulnikMichael ByrneFrancois BernierMamoru YanagimachiKen AoshimaYoshiya OdaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 7, p e69807 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pavan Kumar Zoltan Dezso Crystal MacKenzie Judy Oestreicher Sergei Agoulnik Michael Byrne Francois Bernier Mamoru Yanagimachi Ken Aoshima Yoshiya Oda Circulating miRNA biomarkers for Alzheimer's disease.
description	A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is required to select optimal patient groups in clinical trials, monitor disease progression and response to treatment, and to better plan patient clinical care. Blood is an attractive source for biomarkers due to minimal discomfort to the patient, encouraging greater compliance in clinical trials and frequent testing. MiRNAs belong to the class of non-coding regulatory RNA molecules of ∼22 nt length and are now recognized to regulate ∼60% of all known genes through post-transcriptional gene silencing (RNAi). They have potential as useful biomarkers for clinical use because of their stability and ease of detection in many tissues, especially blood. Circulating profiles of miRNAs have been shown to discriminate different tumor types, indicate staging and progression of the disease and to be useful as prognostic markers. Recently their role in neurodegenerative diseases, both as diagnostic biomarkers as well as explaining basic disease etiology has come into focus. Here we report the discovery and validation of a unique circulating 7-miRNA signature (hsa-let-7d-5p, hsa-let-7g-5p, hsa-miR-15b-5p, hsa-miR-142-3p, hsa-miR-191-5p, hsa-miR-301a-3p and hsa-miR-545-3p) in plasma, which could distinguish AD patients from normal controls (NC) with >95% accuracy (AUC of 0.953). There was a >2 fold difference for all signature miRNAs between the AD and NC samples, with p-values<0.05. Pathway analysis, taking into account enriched target mRNAs for these signature miRNAs was also carried out, suggesting that the disturbance of multiple enzymatic pathways including lipid metabolism could play a role in AD etiology.
format	article
author	Pavan Kumar Zoltan Dezso Crystal MacKenzie Judy Oestreicher Sergei Agoulnik Michael Byrne Francois Bernier Mamoru Yanagimachi Ken Aoshima Yoshiya Oda
author_facet	Pavan Kumar Zoltan Dezso Crystal MacKenzie Judy Oestreicher Sergei Agoulnik Michael Byrne Francois Bernier Mamoru Yanagimachi Ken Aoshima Yoshiya Oda
author_sort	Pavan Kumar
title	Circulating miRNA biomarkers for Alzheimer's disease.
title_short	Circulating miRNA biomarkers for Alzheimer's disease.
title_full	Circulating miRNA biomarkers for Alzheimer's disease.
title_fullStr	Circulating miRNA biomarkers for Alzheimer's disease.
title_full_unstemmed	Circulating miRNA biomarkers for Alzheimer's disease.
title_sort	circulating mirna biomarkers for alzheimer's disease.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/d506b339c5284f2390f8cbdf863dd996
work_keys_str_mv	AT pavankumar circulatingmirnabiomarkersforalzheimersdisease AT zoltandezso circulatingmirnabiomarkersforalzheimersdisease AT crystalmackenzie circulatingmirnabiomarkersforalzheimersdisease AT judyoestreicher circulatingmirnabiomarkersforalzheimersdisease AT sergeiagoulnik circulatingmirnabiomarkersforalzheimersdisease AT michaelbyrne circulatingmirnabiomarkersforalzheimersdisease AT francoisbernier circulatingmirnabiomarkersforalzheimersdisease AT mamoruyanagimachi circulatingmirnabiomarkersforalzheimersdisease AT kenaoshima circulatingmirnabiomarkersforalzheimersdisease AT yoshiyaoda circulatingmirnabiomarkersforalzheimersdisease
_version_	1718421051841445888

Circulating miRNA biomarkers for Alzheimer's disease.

Ejemplares similares